Results 131 to 140 of about 983 (198)
Some of the next articles are maybe not open access.
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea
Annals of Pharmacotherapy, 2020Objective: The purpose of this article is to review the available clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol as well as its role in clinical practice. Data Sources: A MEDLINE/PubMed search was conducted (January 2000 to February 2020) using the keyword solriamfetol to discover appropriate clinical ...
Jason G Powell
exaly +3 more sources
Preclinical Pharmacology of Solriamfetol: Potential Mechanisms for Wake Promotion
CNS Spectrums, 2023 AbstractIntroductionSolriamfetol is a wake-promoting agent (WPA) approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. The wake-promoting mechanism of solriamfetol may result from dopamine and norepinephrine reuptake inhibition.
Hema Gursahani +7 more
openaire +2 more sources
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Expert Review of Clinical Pharmacology, 2019Introduction: Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it. There is currently no cure for narcolepsy, and hence there is a great need for new treatment options. Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.
Junyi, Yang, Junfa, Gao
exaly +3 more sources
Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea
Expert Review of Respiratory Medicine, 2018Introduction: Obstructive sleep apnea (OSA) is highly prevalent and constitutes a major health hazard. Current pharmacotherapy is ineffective in correcting sleep-disordered breathing and is used adjunctively to address residual sleepiness. A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class ...
Vivien C Abad
exaly +3 more sources
Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults
The Journal of Clinical Psychiatry, 2023Objective: Some individuals with attention-deficit/hyperactivity disorder (ADHD) may not tolerate or adequately respond to currently available treatments. This study examined whether solriamfetol could have a favorable pattern of effects and tolerability as a treatment for ADHD in adults.Methods: Sixty adults with DSM-5 ADHD participated from August ...
Craig B H, Surman +5 more
openaire +3 more sources
CNS Drugs, 2023
Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA).
Sheridan M. Hoy
openaire +3 more sources
Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnoea (OSA).
Sheridan M. Hoy
openaire +3 more sources
Solriamfetol for the Management of Excessive Daytime Sleepiness
Journal of Pharmacy Practice, 2021Objective: To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). Methods: PubMed (1966 to January 2021) was searched using the terms solriamfetol, JZP-110, ADX-N05 and Sunosi.
Megan C Cuomo +2 more
openaire +2 more sources
False positive urine amphetamine immunoassay due to solriamfetol
Sleep Medicine, 2023Solriamfetol is a schedule IV-controlled substance used to treat excessive daytime sleepiness resulting from narcolepsy or obstructive sleep apnea. We present a patient prescribed solriamfetol who tested positive for amphetamines on a routine urinary toxicology screen despite patient denial of illicit drug use, raising the possibility of a false ...
Gopal, Kumar +5 more
openaire +2 more sources